Daily Rules, Proposed Rules, and Notices of the Federal Government
Register online for the training course at the registration Web site:
Attendees are responsible for their own accommodations. A block of rooms has been reserved under "FDA Clinical Investigator Course" at the Holiday Inn College Park at a reduced conference rate. Reservations for these accommodations can be made online using the course registration Web site mentioned previously. Click on "registration form." You will see a direct link to the hotel.
Registration materials, payment procedures, accommodation information, and a detailed description of the course can be found at the registration/information Web site mentioned previously.
If you need special accommodations due to a disability, please contact Connie Wisner at least 7 days in advance. Persons attending the course are advised that FDA is not responsible for providing access to electrical outlets.
Clinical trial investigators play a critical role in the development of medical products. They are responsible for ensuring the safe and ethical treatment of study subjects and for collecting adequate and reliable data to support regulatory decisions. This course is intended to assist clinical investigators in understanding what preclinical and clinical information is needed to support the investigational use of medical products, as well as the scientific, regulatory, and ethical considerations involved in the conduct of clinical trials. The course will cover a wide variety of key topics, including material on novel safety concerns, adverse event monitoring, compliance with the legal and ethical obligations of clinical research, and acceptable scientific and analytic standards in the design and conduct of clinical studies. The faculty will include a diverse representation of senior FDA staff, enabling FDA to communicate directly with clinical investigators on issues of greatest importance for successful clinical research.
The training course is designed to provide clinical investigators with an overview of the following information:
* The essential toxicological, pharmacological, and manufacturing data to support investigational drug use in humans;
* Fundamental issues in the design and conduct of clinical trials;
* Statistical and analytic considerations in the interpretation of trial data;
* Appropriate safety evaluation during studies; and
* The ethical considerations and regulatory requirements for clinical trials.
In addition, the course should do the following:
* Foster a cadre of clinical investigators with knowledge, experience, and commitment to investigational medicine;
* Promote communication between clinical investigators and FDA;
* Enhance investigators' understanding of FDA's role in experimental medicine; and
* Improve the quality of data while enhancing subject protection in the performance of clinical trials.
The course will be conducted over 3 days and comprised of approximately 26 lectures, each lasting between 30 and
The course will address FDA's role in clinical studies, regulatory considerations for clinical trials, and review of the material generally appearing in an "investigator's brochure," i.e., the preclinical information (toxicology, animal studies, and chemistry/manufacturing information) that supports initial clinical trials in humans. Presenters will discuss the role of clinical pharmacology in early clinical studies and how this information is used in the design of subsequent studies. The course will also include discussions of scientific, statistical, ethical, and regulatory aspects of clinical studies. On November 15, 2012, participants will choose among three breakout sessions that will explain how to put together an application to FDA for drugs, biologics, or devices.
The course is targeted at health care professionals responsible for, or involved in, the conduct and/or design of clinical trials.